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OBJECTIVE—Observations of elevated circulating concentra-
tions of visfatin (PBEF/Nampt) in obesity and diabetes suggest
that this recently described adipokine is involved in the regula-
tion of body weight and metabolism. We examined in humans
whether visfatin is found in cerebrospinal ﬂuid (CSF) and, if so,
how CSF visfatin concentrations relate to adiposity and meta-
bolic parameters.
RESEARCH DESIGN AND METHODS—We measured visfatin
concentrations in the plasma and CSF of 38 subjects (18 men and
20 women; age 19–80 years) with a wide range of body weight
(BMI 16.24–38.10 kg/m
2). In addition, anthropometric parame-
ters and endocrine markers were assessed. Bivariate correlation
coefﬁcients were determined and stepwise multiple regression
analyses were performed to detect associations of CSF and
plasma visfatin levels with relevant parameters.
RESULTS—Plasma visfatin levels increased with rising BMI
(P  0.0001) and body fat mass (P  0.0001). In contrast, CSF
visfatin levels decreased with increasing plasma visfatin concen-
trations (P  0.03), BMI (P  0.001), body fat mass (P  0.0001),
and insulin resistance (P  0.05). Body fat was the only factor
independently associated with CSF visfatin, explaining 58% of
the variation of CSF visfatin levels (P  0.0001). Neither plasma
(P  0.13) nor CSF (P  0.61) visfatin concentrations differed
between men and women.
CONCLUSIONS—Our data indicate that visfatin concentrations
in human CSF decrease with rising body fat, supporting the
assumption that visfatin transport across the blood-brain barrier
is impaired in obesity and that central nervous visfatin insufﬁ-
ciency or resistance are linked to pathogenetic mechanisms of
obesity. Diabetes 58:637–640, 2009
B
ody weight regulation critically depends on the
interplay between the central nervous system
and endocrine messengers from the periphery,
adipokines like leptin and adiponectin in partic-
ular (1). Visfatin is a recently described peptide, previously
identiﬁed as pre–B-cell colony–enhancing factor (PBEF)
or nicotinamide phosphoribosyltransferase (Nampt), that
is produced by adipose tissue as well as skeletal muscle,
liver, and immune cells (2). The initial assumption that
visfatin acts directly on the insulin receptor and displays
insulin-mimetic properties has been recently cast into
doubt, and still little is known about the role of this
adipokine in energy homeostasis (3–5). Observations of
acutely increased plasma visfatin concentrations during
hyperglycemia have linked visfatin release with regula-
tion of glucose metabolism (6). Moreover, circulating
visfatin levels have been reported to be elevated in
obesity (7,8) and type 2 diabetes (9). These ﬁndings
suggest that visfatin may be actively involved in the
control of weight regulatory networks. On this back-
ground, we investigated the presence of visfatin in
human cerebrospinal ﬂuid (CSF). More importantly, we
also determined CSF concentrations of this adipokine in
relation to corresponding plasma levels as well as to
body weight and adiposity.
RESEARCH DESIGN AND METHODS
Thirty-eight subjects participated in the experiments (18 men and 20 women;
age 19–80 years; BMI 16.24–38.10 kg/m
2). Fourteen participants had normal
body weight, 14 subjects were overweight (BMI 25 to 30 kg/m
2) and 10
subjects were obese (BMI 30 kg/m
2). Exclusion criteria were a history of
diabetes, congestive heart failure, liver or kidney disease, malignancy, signs of
inﬂammation, pregnancy, and any drugs inﬂuencing body weight like corti-
coids or contraceptives. During the study, three subjects (two men and one
woman) were newly diagnosed with type 2 diabetes as indicated by elevated
fasting plasma glucose levels 7 mmol/l according to the criteria of the
American Diabetes Association. After an overnight fast, subjects reported to
the laboratory for simultaneous sampling of blood and cerebrospinal ﬂuid (1
ml) via lumbar puncture after local anesthesia (2 ml mepivacain-HCL 1%). In
addition, body weight, body height, and waist and hip circumferences were
assessed. Body composition was measured by standard bioelectrical imped-
ance analysis (BIA 2000-mol/l; Data Input, Frankfurt, Germany). Frequencies
of 1, 5, 50, and 100 Hz were employed, and Eurobody software (Data Input)
was used to examine body fat mass. The study was approved by the local
ethics committee, and all subjects gave written informed consent.
Blood samples were immediately centrifuged, and plasma and CSF sam-
ples were frozen at 80°C until assay. Visfatin was determined using a
commercially available enzyme immunoassay (Phoenix Pharmaceuticals, Bur-
lingame, CA). Analyses were performed according to the manufacturer’s
protocol, with an intra-assay coefﬁcient of variation (CV) 5% for determina-
tion in CSF and plasma. In addition, plasma and CSF glucose (CV 1.1%;
Beckman glucose analyser II; Beckman Instruments, Fullerton, CA), insulin,
and adiponectin concentrations were measured. Insulin was determined with
a commercial competitive double-antibody radioimmunoassay (Pharmacia
Insulin RIA 100; Pharmacia Diagnostics, Upsalla, Sweden) that was slightly
modiﬁed as described previously (10); the assay limit of sensitivity was 1.8
pmol/l, and intra-assay variation was 4.5% for determination in CSF and
plasma. Adiponectin was determined using a commercially available radioim-
munoassay (HADP-61HK; Linco Research, St. Charles, MO) with a sensitivity
limit of 0.78 ng/ml; intra-assay variation was 6.2%, and interassay variation
was 9.3%. Insulin resistance was estimated employing the homeostatic
model assessment formula, with high scores denoting a high degree of insulin
resistance.
Where necessary, values were log-transformed to achieve normal distribu-
tion. Bivariate Pearson correlation coefﬁcients were determined, and stepwise
multiple regression analyses were performed to detect associations between
CSF visfatin levels and relevant variables (sex, age, body weight, BMI, fat
mass, plasma visfatin, homeostatic model assessment score, waist and hip
circumferences, waist-to-hip ratio, and CSF levels of glucose, insulin, and
adiponectin) as well as between the CSF-to-plasma visfatin ratio and corre-
sponding variables. In addition, plasma and CSF visfatin concentrations were
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DIABETES, VOL. 58, MARCH 2009 637subjected to two-way ANOVA, including the factors sex and, respectively,
body weight status (normal weight/overweight/obese) and body fat quartile,
followed by single comparisons via unpaired Bonferroni corrected t tests. For
analyses, SPSS 15.0 for Windows (SPSS, Chicago, IL) was used. A two-sided P
value 0.05 was considered signiﬁcant.
RESULTS
Table 1 summarizes anthropometric and endocrine param-
eters of our subjects and respective correlations with
visfatin levels in plasma and CSF and with the CSF-to-
plasma visfatin ratio. Plasma visfatin levels increased with
rising body fat mass (Fig. 1A), BMI, and waist and hip
circumferences. In CSF, visfatin was detectable at concen-
trations approximately 10% of plasma levels. Plasma and
CSF visfatin levels were negatively correlated as CSF
visfatin levels decreased with increasing body fat mass
(Fig. 1B), BMI, and waist and hip circumferences, as well
as with increasing insulin resistance and age. Accordingly,
the CSF-to-plasma visfatin ratio was also negatively asso-
ciated with fat mass (Fig. 1C), BMI, and waist and hip
circumferences, as well as with the degree of insulin
resistance, plasma insulin levels, and age. Supporting
analyses relying on Spearman’s rank correlations and
partial correlations including the control variables age and
sex yielded essentially the same results.
In the stepwise multiple linear regression analyses, body
fat mass was the only factor independently associated
with CSF visfatin, explaining 58% of the variation of CSF
visfatin levels (R
2  0.58, B 0.066, SE 0.009 [95% CI
0.085 to 0.047],  0.768, P  0.0001), whereas none of
the other variables, including sex, age, and CSF levels of
glucose, insulin, and adiponectin, were independently re-
lated to CSF visfatin (all P 0.11). With our sample size,
we had 99% power to detect an increment to the model R
2
of 0.58 (at 0.05). Body fat was also the only factor
independently associated with the CSF-to-plasma visfatin
ratio, explaining 64% of the ratio’s variation (R
2  0.64, B
0.004, SE 0.001 [95% CI 0.006 to 0.003],  0.806, P 
0.0001). None of the other parameters, including sex and
age, was independently related to the CSF-to-plasma vis-
fatin ratio (all P  0.12). Exclusion of the three subjects
newly diagnosed with type 2 diabetes did not essentially
alter the results. Again, body fat mass was the only factor
independently correlated with CSF visfatin levels (n  35;
R
2  0.59, B 0.067, SE 0.010 [95% CI 0.087 to 0.047],
 0.773, P  0.0001) and with the CSF-to-plasma visfatin
ratio (R
2  0.61, B 0.004, SE 0.001 [95% CI 0.006 to
0.003],  0.789, P  0.0001).
Strong associations between adiposity and plasma and
CSF visfatin concentrations were conﬁrmed by compari-
sons across body fat quartiles (Table 2). Plasma visfatin
levels of subjects in the highest quartile signiﬁcantly
exceeded those of subjects in the other quartiles
[F(3,30)  8.72, P  0.0001, for main effect of body fat
quartile] and a reverse pattern was observed for CSF
visfatin levels [F(3,30)  16.38, P  0.0001]. Correspond-
ing results were obtained when obese subjects were
compared with normal-weight and overweight subjects
[plasma visfatin F(2,32)  8.64, P  0.001; CSF visfatin
F(2,32)  6.42, P  0.005, for main effects of body weight
status]. Visfatin concentrations were comparable be-
tween men and women in plasma [F(1,30)  2.46, P 
0.13, for main effect of sex] and CSF [F(1,30)  0.27, P 
0.61]. Also, the factor sex did not statistically interact
with measures of body fat (all P  0.10), excluding
pronounced effects of sex on visfatin concentrations in
plasma and CSF.
TABLE 1
Subject characteristics and correlations with plasma and CSF visfatin concentrations and the CSF-to-plasma visfatin ratio
Mean  SEM Plasma visfatin CSF visfatin
CSF-to-plasma
visfatin ratio
Age (years) 53.26  2.58 0.23 0.36* 0.34*
BMI (kg/m
2) 26.67  0.76 0.69† 0.52† 0.73†
Body weight (kg) 77.99  2.81 0.71† 0.47‡ 0.70†
Fat mass (kg) 22.56  1.64 0.71† 0.68† 0.80†
Waist circumference (cm) 95.11  2.37 0.59† 0.48‡ 0.65†
Hip circumference (cm) 99.73  1.82 0.61† 0.57† 0.72†
Waist-to-hip ratio 0.95  0.01 0.32 0.18 0.30
Visfatin
Plasma (ng/ml) 33.58  2.49 — — —
CSF (ng/ml) 3.41  0.12 0.36* — —
CSF-to-plasma ratio 0.12  0.01 0.86† 0.74† —
Glucose
Plasma (mmol/l) 5.14  0.12 0.20 0.20 0.24
CSF (mmol/l) 3.31  0.07 0.21 0.16 0.28
CSF-to-plasma ratio 0.65  0.01 0.03 0.00 0.08
Insulin
Plasma (pmol/l) 84.35  10.56 0.23 0.32* 0.33*
CSF (pmol/l) 2.23  0.19 0.04 0.07 0.08
CSF-to-plasma ratio 0.037  0.004 0.24 0.28 0.31
HOMA 3.36  0.51 0.25 0.33* 0.35*
Adiponectin
Plasma (g/ml) 12.24  0.85 0.22 0.03 0.12
CSF (ng/ml) 6.02  1.19 0.12 0.20 0.03
CSF-to-plasma ratio 0.00046  0.00004 0.11 0.12 0.12
Plasma levels of visfatin and insulin, CSF insulin concentrations, and HOMA values were log-transformed prior to correlational analyses to
achieve normal distribution. n  38. *P  0.05, †P  0.001, ‡P  0.01. CSF, cerebrospinal ﬂuid; HOMA, insulin resistance as calculated by
the homeostatic model assessment formula.
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Our results indicate that visfatin is present in human CSF
and, furthermore, that CSF visfatin concentrations de-
crease in conjunction with increasing adiposity. We also
found a strong positive association between plasma visfa-
tin levels and body fat mass, body weight, and waist and
hip circumferences. This observation conﬁrms previous
results indicating that obesity (7,8) and type 2 diabetes
(9,11) are linked to elevated circulating visfatin concentra-
tions. Accordingly, massive weight loss is accompanied by
a drop in plasma visfatin (12). Other studies have indicated
no association between body fat and plasma visfatin (13)
or have even reported on reduced visfatin levels in obesity
(14). The initial assumption that visceral fat is the deter-
mining factor in visfatin production (3) has likewise been
challenged (4,7). However, increases in visfatin mRNA in
visceral adipose tissue of obese subjects and a positive
correlation between BMI and visceral visfatin mRNA have
been observed even in the absence of an association
between circulating visfatin concentrations and body fat
(14). More recently, visfatin has been shown to be secreted
by adipocytes through a nonclassical secretory pathway
that probably represents a highly regulated process (5,15).
Therefore, plasma in comparison with cellular levels of the
adipokine may display greater variance, which, in conjunc-
tion with the fact that visfatin is abundantly produced by
the stromal vascular fraction of adipose tissue (16) and
that relatively low levels of circulating visfatin are found
under physiological conditions, might explain the conﬂict-
ing results on plasma visfatin in obesity. Our observations
agree with the majority of previous studies (7–9,11,12)
indicating that plasma visfatin concentrations increase
with rising adiposity.
To our knowledge, this is the ﬁrst study investigating the
presence of visfatin in CSF. Our results indicate that in
humans visfatin is found in CSF at concentrations that are
	10% of those in plasma. It is not yet known whether the
peptide penetrates the central nervous system from the
circulation. Leptin, an adipokine that is considerably
smaller than visfatin (16 vs. 52 kDa; 167 vs. 473 amino
acids), crosses the blood-brain barrier (BBB) via an active,
saturable transport system (17) and displays a 5- to 10-fold
less pronounced CSF-to-plasma ratio than that observed
for visfatin in the present experiments (18). This pattern
suggests that circulating visfatin can likewise enter the
brain compartment, probably also via an active transport
mechanism, although it cannot be ruled out that there are
central nervous secretion sites for the peptide (19). In our
study, CSF visfatin levels decreased with increasing
plasma visfatin levels and adiposity, supporting the as-
sumption that visfatin transport across the BBB is im-
paired when circulating visfatin increases as a result of
excess body fat. However, this preliminary conclusion is in
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FIG. 1. Correlation of body fat mass with plasma visfatin concentration
(A), CSF visfatin concentration (B), and CSF-to-plasma visfatin ratio
(C). For statistical analyses, plasma visfatin levels were log-trans-
formed to achieve a normal distribution. , subjects newly diagnosed
with type 2 diabetes.
TABLE 2
Plasma and CSF visfatin concentrations with respect to body fat,
body weight status, and sex
Plasma
visfatin
(ng/ml) P*
CSF
visfatin
(ng/ml) P*
Body fat quartile
1 24.87  0.96 0.001 4.22  0.18† 0.0001
2 28.58  2.17 0.001 3.55  0.57 0.003
3 29.92  2.28 0.01 3.27  0.19 NS
4 49.71  6.81 2.66  0.14
Body weight status
Normal weight 26.43  1.58 0.002 3.81  0.24‡ 0.005
Overweight 29.45  1.75 0.004 3.32  0.14 NS
Obese 49.37  6.86 2.98  0.20
Sex
Male 35.56  4.19 3.50  0.16
Female 31.79  2.89 3.33  0.19
Data are means  SEM. n  38: 18 men and 20 women; 14
normal-weight subjects, 14 overweight subjects (BMI 25 to 30
kg/m
2), and 10 obese subjects (BMI 30 kg/m
2). Differences between
men and women were not signiﬁcant. *For comparisons with body
fat quartile 4 and obesity, respectively. †P  0.015 and 0.002 for
comparison with body fat quartiles 2 and 3, respectively. ‡P  0.03
for comparison with overweight.
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transport of visfatin across the BBB in normal weight and
obesity. Moreover, although we could exclude a signiﬁcant
inﬂuence of sex and age on CSF visfatin levels in our
study, the potential contribution of, e.g., sex-speciﬁc en-
docrine factors (20) to the observed pattern still has to be
examined.
Adiposity turned out to be the only variable indepen-
dently associated with the variance of CSF levels and the
CSF-to-plasma ratio of visfatin, suggesting obesity to be
closely connected with reduced CSF visfatin levels. With
the physiological role of visfatin in energy homeostasis far
from being elucidated, low CSF visfatin levels may be a
mere by-product of increased body fat stores. However,
remarkably similar patterns have been revealed for leptin
(18,21) and insulin (10,22), two endocrine adiposity signals
that provide the brain with negative feedback on the
amount of body fat. Dysfunctional central nervous insulin
and leptin signaling has been well established as a key
feature of obesity (1), and preliminary ﬁndings in animals
hint at the involvement of central nervous visfatin in the
regulation of food intake (23). Plasma visfatin levels are
reduced by diet-induced weight loss in obese nondiabetic
patients (24) and by exercise in patients with type 1
diabetes (25), and it remains to be seen whether these
clinical interventions in turn increase central nervous
levels of the peptide. In sum, our results support the
intriguing, albeit tentative, assumption that central ner-
vous visfatin insufﬁciency or resistance might be linked to
pathogenetic mechanisms of obesity.
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